全文获取类型
收费全文 | 24490篇 |
免费 | 2533篇 |
国内免费 | 492篇 |
专业分类
耳鼻咽喉 | 202篇 |
儿科学 | 251篇 |
妇产科学 | 566篇 |
基础医学 | 2392篇 |
口腔科学 | 193篇 |
临床医学 | 2444篇 |
内科学 | 3521篇 |
皮肤病学 | 214篇 |
神经病学 | 616篇 |
特种医学 | 604篇 |
外科学 | 2126篇 |
综合类 | 2227篇 |
一般理论 | 2篇 |
预防医学 | 2680篇 |
眼科学 | 56篇 |
药学 | 1875篇 |
11篇 | |
中国医学 | 551篇 |
肿瘤学 | 6984篇 |
出版年
2024年 | 37篇 |
2023年 | 549篇 |
2022年 | 980篇 |
2021年 | 1436篇 |
2020年 | 1139篇 |
2019年 | 1574篇 |
2018年 | 1551篇 |
2017年 | 1323篇 |
2016年 | 951篇 |
2015年 | 1003篇 |
2014年 | 1995篇 |
2013年 | 1840篇 |
2012年 | 1355篇 |
2011年 | 1424篇 |
2010年 | 1018篇 |
2009年 | 1074篇 |
2008年 | 1262篇 |
2007年 | 1024篇 |
2006年 | 799篇 |
2005年 | 657篇 |
2004年 | 587篇 |
2003年 | 452篇 |
2002年 | 295篇 |
2001年 | 312篇 |
2000年 | 265篇 |
1999年 | 250篇 |
1998年 | 210篇 |
1997年 | 192篇 |
1996年 | 192篇 |
1995年 | 152篇 |
1994年 | 160篇 |
1993年 | 113篇 |
1992年 | 90篇 |
1991年 | 71篇 |
1990年 | 62篇 |
1989年 | 75篇 |
1988年 | 53篇 |
1987年 | 51篇 |
1986年 | 35篇 |
1985年 | 104篇 |
1984年 | 130篇 |
1983年 | 101篇 |
1982年 | 129篇 |
1981年 | 87篇 |
1980年 | 79篇 |
1979年 | 77篇 |
1978年 | 48篇 |
1977年 | 31篇 |
1976年 | 35篇 |
1975年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
《Transfusion and apheresis science》2022,61(4):103488
The COVID-19 pandemic caused by the SARS-CoV-2 virus has significantly disrupted and burdened the diagnostic workup and delivery of care, including transfusion, to cancer patients across the globe. Furthermore, cancer patients suffering from solid tumors or hematologic malignancies were more prone to the infection and had higher morbidity and mortality than the rest of the population. Major signaling pathways have been identified at the intersection of SARS-CoV-2 and cancer cells, often leading to tumor progression or alteration of the tumor response to therapy. The reactivation of oncogenic viruses has also been alluded to in the context and following COVID-19. Paradoxically, certain tumors responded better following the profound infection-induced immune modulation. Unveiling the mechanisms of the virus-tumor cell interactions will lead to a better understanding of the pathophysiology of both cancer progression and virus propagation. It would be challenging to monitor, through the different cancer registries, retrospectively, the response of patients who have been previously exposed to the virus in contrast to those who have not contracted the infection. 相似文献
6.
7.
《Bulletin du cancer》2023,110(2):145-150
8.
9.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
10.